Molecular cloning and functional characterization of inhibitor-sensitive (mENT1) and inhibitor-resistant (mENT2) equilibrative nucleoside transporters from mouse brain

Biochemical Journal

Volumn 352, Issue 2, 2000, Pages 363-372

  Kiss, A ^a   Farah, K ^a   Kim, J ^a   Garriock, R J ^a   Drysdale, T A ^a   Hammond, J R ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Dipyridamole; Nitrobenzylthioinosine; Nucleoside transport; Transporter isoforms; Xenopus oocytes

Indexed keywords

ADENOSINE; CARRIER PROTEIN; DILAZEP; DIPYRIDAMOLE; DRAFLAZINE; NUCLEOSIDE TRANSPORT PROTEIN ENT1; NUCLEOSIDE TRANSPORT PROTEIN ENT2; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MEMBRANE STRUCTURE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; XENOPUS;

5' UNTRANSLATED REGIONS; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BRAIN; CARRIER PROTEINS; CLONING, MOLECULAR; DNA PRIMERS; DNA, COMPLEMENTARY; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; NUCLEOSIDE TRANSPORT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; XENOPUS LAEVIS;

ANIMALIA; MAMMALIA; MURINAE;

EID: 0034533226     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/0264-6021:3520363     Document Type: Article

References (51)

1. Nucleoside transport and its significance for anticancer drug resistance
2. Nucleoside transport in normal and neoplastic cells
3. Neuroprotective actions of dipyridamole on cultured CNS neurons
4. Adenosine uptake site heterogeneity in the mammalian CNS? Uptake inhibitors as probes and potential neuropharmaceuticals
5. Adenosine transport in the CNS
6. Adenosine-based therapeutics in neurologic disease
7. Adenosine: A prototherapeutic concept in neurodegeneration
8. Role of adenosine in the heart and circulation
9. Protective effects of adenosine in myocardial ischemia
10. Differential cardioprotection with selective inhibitors of adenosine metabolism and transport: Role of purine release in ischemic and repedusion injury
11. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection
12. Nucleoside transport inhibition: A therapeutic approach to cardioprotection via adenosine?
13. The control of the metabolism and the hormonal role of adenosine
14. Nucleoside transporters: Molecular biology and implications for therapeutic development
15. Recent advances in the molecular biology of nucleoside transporters of mammalian cells
16. Nucleoside and nucleobase transport systems of mammalian cells
17. Nucleoside transport and metabolism in lymphocytes, polymorphonuclear cells and cerebral synaplosomes
18. The biological significance of purine salvage
19. Nucleoside transport inhibitors: Structure-activity relationships and potential therapeutic applications
20. Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells
21. Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species
22. 3H]nitrobenzylthioinosine to the nucleoside transport system in mammalian central nervous system membranes: Evidence for interconvertible conformations of the binding site/transporter complex
23. Competition of nucleoside transport inhibitors with binding of 6-[(4-nitrobenzyl)-mercapto]purine ribonucleoside to intact erythrocytes and ghost membranes from different species
24. Species differences in sensitivity or nucleoside transport in erythrocytes and cultured cells to inhibition by nitrobenzylthioinosine, dipyridamole, dilazep, and lidoflazine
25. Adenosine transport by rat and guinea pig synaptosomes: Basis for differential sensitivity to transport inhibitors
26. Differential inhibition of nucleoside transport systems in mammalian cells by a new series of compounds related to lidoflazine and mioflazine
27. Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta
28. Cloning of a human nucleoside transporter implicated in the cellular uptake or adenosine and chemotherapeutic drugs
29. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line
30. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (el) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from raf tissues
31. +-dependent nucleoside transport systems of rat infestine in isolated oocytes of Xenopus laevis. Demonstration that rat jejunum expresses the purine-selective system N1 (cif) and a second, novel system N3 having broad specificity for purine and pyrimidine nucleosides
32. 3H]guanosine by nucleoside transporter subtypes in Ehrlich ascites tumour cells
33. +-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells
34. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: Species differences and transporter subtype selectivity
35. Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium
36. A new concept of long-term donor heart preservation: Nucleoside transport inhibition J
37. Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs
38. Inhibitors of nucleoside transport A structure-activity study using human erythrocytes
39. Solubilization and reconstitution of a nucleoside-transport system from Ehrlich ascites-tumour cells
40. Enzymic cleavage as a probe of the molecular structures of mammalian equilibrative nucleoside transporters
41. Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Inferaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/n48q)
42. Control of nucleoside transport in neural cells. Effect of protein kinase C activation
43. +-dependent uridine-transport sysytem. Involvement of protein kinase C
44. Decrease in equilibrative uridine transport during monocytic differentiation of HL-60 leukaemia: Involvement of protein kinase C
45. Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes
46. Effects of phorbol esters and secretagogues on nitrobenzylthicinosine binding to nucleoside transporters and nucleoside uptake in cultured chromaffin cells
47. SH3 domains. Minding your p's and q's
48. High-resolution crystal structures of tyrosine kinase SH3 dcmains complexed with proline-rich peptides
49. A mammalian delayed-early response gene encodes HNP36. A novel, conserved nucleolar protein
50. The human HNP36 gene is localized to chromosome 11q13 and produces alternative transcripts that are not mutated in multiple endocrine neoplasia, type 1 (MEN I) syndrome
51. Demonstration of equilibrative nucleoside transporters (hENT1 and hENT2) in nuclear envelopes of cultured human choriocarcinoma (BeWo) cells by functional reconstitution in proteoliposomes